Purpose Pharmacokinetic considerations in patients who have undergone Roux-en-Y gastric bypass (RYGB) are explored. Summary The prevalence of obesity, especially morbid obesity, has dramatically ...

Following surgery, there were 1,651 adverse events (6.0, 4.6, and 5.7 per year after Roux-en-Y gastric bypass, adjustable gastric banding, and sleeve gastrectomy, respectively).

Creation of the small stomach pouch and the small anastomosis for food and drugs ... or altered mesenteric blood flow. a RYGB = Roux-en-Y gastric bypass, Mct1 = monocarboxylic acid transporter ...